Oncology
News
Microscopic Vascular Invasion May Be a Powerful Prognosticator in Early Lung Cancer
Major Finding: Five-year overall survival was 50% for patients with microscopic vascular invasion vs. 66% for those without MVI (P = .001).Data...
News
Fentanyl Transmucosal Tablets Approved for Breakthrough Cancer Pain
News
No Increased Cancer Risk Seen in Stem Cell, Marrow Donors
Major Finding: The standard incidence ratio for all malignancies among all donors was 0.99.Data Source: Survey based on 55,228 observation-years...
News
Chemotherapy Sequence Affects Early Breast Cancer Outcomes
Major Finding: The 5-year overall survival rate was 93.1% with paclitaxel followed by anthracyclines as adjuvant therapy compared with 83.2% for...
News
Liposomal Cytarabine-Daunorubicin Improves AML Remission Rates
Major Finding: Novel CPX-351 was associated with significantly better overall survival in a subgroup of patients with secondary AML (median, 12.1...
News
Young Adult AML Patients Fare Better on Children's Protocol
Major Finding: Overall survival 10 years after study entry was 45% in Children’s Oncology Group trials vs.
News
Romidepsin Induces Complete Response in Peripheral T-Cell Lymphoma
Major Finding: Romidepsin was associated with a 13% complete response rate in patients with peripheral T-cell lymphoma that had relapsed or was...
News
Bevacizumab Maintenance Extends Lung Cancer Survival in Community Practice
Major Finding: Median overall survival was 20.9 months among patients who continued on bevacizumab until disease progression vs. 10.2 months among...
News
Seroma After Breast Cancer Surgery Triples Lymphedema Risk
Major Finding: Based on the International Criteria for Lymphedema Diagnosis, 26 of 35 women with a seroma had severe lymphedema, 6 had moderate...
News
Alemtuzumab Reduces Minimal Residual Disease in CLL Patients
Major Finding: Alemtuzumab was associated with negative MRD in 83% of patients with CLL when it was used for 6 weeks after conclusion of...
News
In Good-Risk Breast Cancer, Longer Chemotherapy Isn't Better
Major Finding: With a median follow-up of 4.6 years, the relapse-free survival rate was 91.6% in patients who received six cycles of chemotherapy...